Nuvation Bio Inc. (NYSE:NUVB) Given Average Recommendation of “Moderate Buy” by Brokerages

Nuvation Bio Inc. (NYSE:NUVB) has received an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $12.50.

A number of equities analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Nuvation Bio in a research note on Tuesday, May 5th. Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Nuvation Bio in a research note on Tuesday, May 5th. Truist Financial set a $13.00 target price on Nuvation Bio in a research report on Tuesday, January 27th. UBS Group reduced their target price on Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 3rd. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $20.00 target price on shares of Nuvation Bio in a research report on Tuesday, May 5th.

Nuvation Bio Stock Performance

Shares of NYSE:NUVB opened at $4.78 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.44 and a quick ratio of 6.81. The business’s 50 day moving average price is $4.68 and its 200-day moving average price is $5.95. The firm has a market capitalization of $1.66 billion, a PE ratio of -11.10 and a beta of 1.51. Nuvation Bio has a 1 year low of $1.57 and a 1 year high of $9.75.

Nuvation Bio (NYSE:NUVB) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.04. The firm had revenue of $83.23 million for the quarter, compared to analyst estimates of $66.22 million. Nuvation Bio had a negative return on equity of 44.10% and a negative net margin of 102.06%. As a group, equities research analysts expect that Nuvation Bio will post -0.52 earnings per share for the current fiscal year.

Insider Buying and Selling at Nuvation Bio

In related news, insider Kerry Wentworth sold 36,750 shares of the business’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $5.01, for a total value of $184,117.50. Following the sale, the insider owned 53,000 shares in the company, valued at approximately $265,530. The trade was a 40.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dongfang Liu sold 50,000 shares of the company’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $5.02, for a total value of $251,000.00. Following the sale, the insider owned 18,000 shares in the company, valued at approximately $90,360. This trade represents a 73.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 286,750 shares of company stock worth $1,339,118 in the last quarter. Company insiders own 30.11% of the company’s stock.

Institutional Investors Weigh In On Nuvation Bio

Several large investors have recently bought and sold shares of NUVB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Nuvation Bio by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 108,547 shares of the company’s stock worth $191,000 after acquiring an additional 4,608 shares in the last quarter. Millennium Management LLC boosted its position in shares of Nuvation Bio by 52.4% during the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock worth $6,642,000 after acquiring an additional 1,298,131 shares in the last quarter. Envestnet Asset Management Inc. acquired a new position in shares of Nuvation Bio during the 2nd quarter worth about $92,000. Creative Planning boosted its position in shares of Nuvation Bio by 267.1% during the 2nd quarter. Creative Planning now owns 39,288 shares of the company’s stock worth $77,000 after acquiring an additional 28,585 shares in the last quarter. Finally, Cetera Investment Advisers acquired a new position in shares of Nuvation Bio during the 2nd quarter worth about $29,000. Hedge funds and other institutional investors own 61.67% of the company’s stock.

Key Stories Impacting Nuvation Bio

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Regulatory progress could help sentiment: Nuvation Bio announced FDA acceptance of its supplemental New Drug Application for IBTROZI (taletrectinib), including updated duration-of-response data in advanced ROS1-positive non-small cell lung cancer. Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI®
• Positive Sentiment: Broker sentiment remains constructive overall, with Nuvation Bio receiving a consensus “Moderate Buy” recommendation and additional upbeat calls from Wedbush, HC Wainwright, and RBC Capital. Nuvation Bio Given Consensus Recommendation of Moderate Buy by Brokerages
• Neutral Sentiment: HC Wainwright kept a Buy rating and $17 price target, but trimmed its 2026 EPS estimates slightly, reflecting a somewhat more cautious near-term earnings outlook. Nuvation Bio Earns Buy Rating from HC Wainwright
• Neutral Sentiment: Wedbush reiterated an Outperform rating, reinforcing expectations that analysts still see longer-term upside despite recent volatility. Wedbush Reiterates Outperform Rating for Nuvation Bio
• Negative Sentiment: A shareholder investigation by Purcell & Lefkowitz adds legal and governance risk, which can pressure biotech stocks as investors worry about potential corporate-action issues. Shareholder Alert: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.